Peter Lebowitz
Affiliations: | Oncology | Johnson & Johnson Pharmacuetical Research and Development, Gurugram, PA, United States |
Google:
"Peter Lebowitz"Mean distance: (not calculated yet)
Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Du W, Lebowitz PF, Prendergast GC. (1999) Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors. Cancer Research. 59: 2059-63 |
| Du W, Lebowitz PF, Prendergast GC. (1999) Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Molecular and Cellular Biology. 19: 1831-40 |
| Lebowitz PF, Prendergast GC. (1998) Functional interaction between RhoB and the transcription factor DB1. Cell Adhesion and Communication. 6: 277-87 |
| Lebowitz PF, Prendergast GC. (1998) Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 17: 1439-45 |
| Lebowitz PF, Du W, Prendergast GC. (1997) Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. The Journal of Biological Chemistry. 272: 16093-5 |
| Lebowitz PF, Casey PJ, Prendergast GC, et al. (1997) Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. The Journal of Biological Chemistry. 272: 15591-4 |
| Lebowitz PF, Sakamuro D, Prendergast GC. (1997) Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Research. 57: 708-13 |
| Prendergast GC, Davide JP, Lebowitz PF, et al. (1996) Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors Cancer Research. 56: 2626-2632 |
| Lebowitz PF, Davide JP, Prendergast GC. (1995) Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Molecular and Cellular Biology. 15: 6613-22 |
| Prendergast GC, Khosravi-Far R, Solski PA, et al. (1995) Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 10: 2289-96 |